{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:16:37Z","timestamp":1792106197535,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted inhibition of Rho-associated kinase (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of the immune response in animals models of autoimmunity and Th17-skewing human cell culture in vitro. In this study, we report that oral administration of a selective ROCK2 inhibitor, KD025, reduces psoriasis area and severity index scores by 50% from baseline in 46% of patients with psoriasis vulgaris, and it decreases epidermal thickness as well as T cell infiltration in the skin. We observed significant reductions of IL-17 and IL-23, but not IL-6 and TNF-\u03b1, whereas IL-10 levels were increased in peripheral blood of clinical responders after 12 wk of treatment with KD025. Collectively, these data demonstrate that an orally available selective ROCK2 inhibitor downregulates the Th17-driven autoimmune response and improved clinical symptoms in psoriatic patients via a defined molecular mechanism that involves concurrent modulation of cytokines without deleterious impact on the rest of the immune system.<\/jats:p>","DOI":"10.4049\/jimmunol.1602142","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T20:30:29Z","timestamp":1491597029000},"page":"3809-3814","source":"Crossref","is-referenced-by-count":91,"title":["Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10"],"prefix":"10.1093","volume":"198","author":[{"given":"Alexandra","family":"Zanin-Zhorov","sequence":"first","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M","family":"Weiss","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-0098","authenticated-orcid":false,"given":"Alissa","family":"Trzeciak","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Zhang","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie S","family":"Nyuydzefe","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Arencibia","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetharam","family":"Polimera","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Schueller","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-1302","authenticated-orcid":false,"given":"Judilyn","family":"Fuentes-Duculan","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Bonifacio","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Kunjravia","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Cueto","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"Southern California Dermatology, Inc. , Santa Ana, CA 92701"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center , Dallas, TX 75231"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research , Duncanville, PA 16635"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY 10029"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-3398","authenticated-orcid":false,"given":"Margarita","family":"Nunez","sequence":"additional","affiliation":[{"name":"High Point Clinical Trials Center , High Point, NC 27265"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnnie","family":"Woodson","sequence":"additional","affiliation":[{"name":"Clinical Studies Group, LLC , Henderson, NV 89074"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shondra L","family":"Smith","sequence":"additional","affiliation":[{"name":"Dermatology & Advanced Aesthetics , Lake Charles, LA 70605"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"West","sequence":"additional","affiliation":[{"name":"Arrowhead Health Centers , Glendale, AZ 85306"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berger","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Krueger","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, Rockefeller University , New York, NY 10065"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Ryan","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D","family":"Waksal","sequence":"additional","affiliation":[{"name":"Kadmon Corporation, LLC , New York, NY 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"2025030615141574000_r1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"2025030615141574000_r2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/BOR.0000000000000274","article-title":"New therapies for psoriasis and psoriatic arthritis","volume":"28","author":"Ritchlin","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"2025030615141574000_r3","first-page":"1","article-title":"Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis","volume":"18","author":"Mudigonda","year":"2012","journal-title":"Dermatol. Online J."},{"key":"2025030615141574000_r4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"2025030615141574000_r5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"key":"2025030615141574000_r6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"2025030615141574000_r7","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.0903162","article-title":"IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation","volume":"184","author":"Roussel","year":"2010","journal-title":"J. Immunol."},{"key":"2025030615141574000_r8","first-page":"311","article-title":"Anti-IL-17 agents for psoriasis: a review of phase III data","volume":"15","author":"Farahnik","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"2025030615141574000_r9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14656566.2016.1109636","article-title":"Novel systemic therapies for the treatment of psoriasis","volume":"17","author":"Tan","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"2025030615141574000_r10","first-page":"1","article-title":"A review of ixekizumab, an anti-interleukin-17A monoclonal antibody, for moderate-to-severe plaque psoriasis","volume":"21","author":"Peranteau","year":"2016","journal-title":"Skin Therapy Lett."},{"key":"2025030615141574000_r11","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"2025030615141574000_r12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2014.11.028","article-title":"Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis","volume":"72","author":"D\u2019Souza","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"2025030615141574000_r13","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2025030615141574000_r14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4049\/jimmunol.178.3.1938","article-title":"Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus","volume":"178","author":"Li","year":"2007","journal-title":"J. Immunol."},{"key":"2025030615141574000_r15","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030615141574000_r16","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 suppresses murine and human chronic GVHD through a Stat3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"key":"2025030615141574000_r17","doi-asserted-by":"crossref","first-page":"ra73","DOI":"10.1126\/scisignal.aad8953","article-title":"ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings","volume":"9","author":"Weiss","year":"2016","journal-title":"Sci. Signal."},{"key":"2025030615141574000_r18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cyto.2014.12.025","article-title":"ROCKing cytokine secretion balance in human T cells","volume":"72","author":"Zanin-Zhorov","year":"2015","journal-title":"Cytokine"},{"key":"2025030615141574000_r19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acn3.19","article-title":"Selective ROCK2 inhibition in focal cerebral ischemia","volume":"1","author":"Lee","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2025030615141574000_r20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jim.2015.04.017","article-title":"A fully-automated, six-plex single molecule immunoassay for measuring cytokines in blood","volume":"424","author":"Rivnak","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"2025030615141574000_r21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MBC.0b013e32830b2891","article-title":"Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin","volume":"19","author":"Boerma","year":"2008","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"2025030615141574000_r22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/scrt449","article-title":"The effect of Rho kinase inhibition on long-term keratinocyte proliferation is rapid and conditional","volume":"5","author":"Chapman","year":"2014","journal-title":"Stem Cell Res. Ther."},{"key":"2025030615141574000_r23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"2025030615141574000_r24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40257-016-0179-3","article-title":"Novel oral therapies for psoriasis and psoriatic arthritis","volume":"17","author":"Yiu","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"2025030615141574000_r25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/10\/3809\/61451960\/1602142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/10\/3809\/61451960\/1602142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:32:54Z","timestamp":1741264374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/198\/10\/3809\/7955791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1602142","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2017,5]]}}}